 |
 |
 |
 |
Sitemap
- Gallery
- Pertandingan Perarakan (Parade) sempena Majlis Perasmian Sambutan Ulang Tahun Bandaraya Petaling Jaya ke-18 dan Pra-Pelancaran Petaling Jaya International Folklore Festival 2025
- Kunjungan Hormat oleh Mr. Micheal Wiseman, Ketua Cawangan Regulatori Antarabangsa, Therapeutic Goods Administration (TGA), Australia
- Lawatan Kerja Rasmi YB Menteri Kesihatan Malaysia ke NPRA
- Vaccine Announcement
- Tawaran Iklan Sebut Harga
- Safety Alerts 2019
- Carbimazole and methimazole (thiamazole): (i) Risk of birth defects and neonatal disorders in case of exposure during pregnancy; (ii) Risk of pancreatitis
- Benlysta® (belimumab): Increased risk of serious psychiatric events
- DARZALEX (daratumumab): New identified risk of Hepatitis B Virus reactivation
- Deferiprone: Risk of neurological disorders in children
- Posaconazole: Pseudohyperaldosteronism
- TECENTRIQ® (atezolizumab): A new important identified risk – immune-related myositis
- Imovane® (zopiclone): New restriction of the indication and additional warnings on abuse and dependence
- Actemra® (tocilizumab): New important identified risk of hepatotoxicity
- Diclofenac (systemic use): (i) Risk of anastomotic leakage and (ii) Risk of Kounis syndrome
- LEMTRADA® (alemtuzumab): (i) Risk of autoimmune hepatitis (ii) Other serious reactions temporally associated with alemtuzumab infusion (iii) Haemophagocytic lymphohistiocytosis
- Clopidogrel: Interaction with boosted antiviral Human Immunodeficiency Virus (HIV) therapy leading to insufficient inhibition of platelet aggregation
- Smecta® (dioctahedral smectite): Not recommended for use in children aged below 2 years and pregnant or breastfeeding women
- FEBURIC® (febuxostat): Increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study
- Retinoids: Updated measures for pregnancy prevention during retinoids use
- Oral retinoids: Risk of neuropsychiatric symptoms
- Tapentadol: Risk of seizures and reports of serotonin syndrome when co-administered with other drugs
- Xylometazoline: Increased risk of serious ventricular arrhythmia in patients with long QT syndrome
- Direct-Acting Antivirals (DAAVs) : Risk of hypoglycaemia in patients with diabetes
- Beta-Lactam antibiotics: Severe Cutaneous Adverse Reactions (SCARs)
- Ceftriaxone: Disturbed consciousness, convulsions or involuntary movements
- Lamotrigine: Risk of hemophagocytic lymphohistiocytosis (HLH)
- Acetazolamide: A new contraindication during pregnancy
- Fluoroquinolones: Risk of aortic aneurysm and dissection
- Epilim® (Sodium Valproate): Important new restrictions on use
- Safety Alerts 2020
- New safety measure for sodium valproate: (i) Risk of congenital malformation in neonates and neurodevelopmental problems in children exposed to sodium valproate during pregnancy; (ii) Additional educational material for healthcare professionals and patients/caretakers
- Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors: Risk of severe lung inflammation
- Ondansetron: Birth defects
- Sulfasalazine: Interference with dihydronicotinamide-adenine dinucleotide/ dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADPH) reaction assays
- Esbriet® (pirfenidone): Drug-induced liver injury (DILI)
- Kyprolis® (carfilzomib): (i) Risk of progressive multifocal leukoencephalopathy (PML); (ii) Risk of hepatitis B virus (HBV) reactivation
- Nivolumab: Reports of cytomegalovirus (CMV) infection or reactivation
- Intravenous iron-containing products: Kounis syndrome
- Esmya (ulipristal acetate 5 mg): Product recall due to potential risk of liver injury
- Guselkumab: Risk of anaphylaxis
- Nintedanib: Ischaemic colitis
- Rocuronium: Kounis syndrome
- Gabapentin: Risk of dysphagia
- Proton pump inhibitors: Risk of microscopic colitis
- Domperidone: Restriction of use in paediatric patients less than 12 years of age
- Reminder on the risk of oculogyric crisis with metoclopramide use
- Insulin: Risk of cutaneous amyloidosis
- Topiramate: Risk of uveitis
- Plaquenil® (hydroxycholoroquine): Risk of QT prolongation and other drug-drug interactions in the context of COVID-19 management
- Propofol: Risk of priapism
- Parenteral nutrition containing amino acids and/or lipids: Risk of toxic degradations of ingredients when exposed to light, which may lead to adverse outcomes in paediatric patients less than 2 years of age
- Gilenya® (fingolimod): New contraindication in pregnant women and in women of childbearing potential who are not using effective contraception
- Esmya (ulipristal acetate 5 mg): Withdrawal of product registration
- Safety Alerts 2021
- Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]
- Clindamycin: Risk of Acute Renal Failure
- Sulfamethoxazole & Trimethoprim (Co-Trimoxazole): Risk of Acute Respiratory Distress Syndrome (ARDS)
- Decitabine: Risk of Differentiation Syndrome
- Anastrozole: Risk of Depression
- Vascular endothelial growth factor (VEGF) inhibitors for systemic use (except application on eyes): Risk of artery dissections and aneurysms
- Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)
- Antidepressants (citalopram; desvenlafaxine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine; vortioxetine): Risk of Postpartum Haemorrhage (PPH)
- Oseltamivir: Risk of Haemorrhages
- Mycophenolate Mofetil (MMF) and Myocophenolic Acid (MPA): Risk of De Novo Purine Synthesis Inhibitors-Associated Acute Inflammatory Syndrome
- Sacubitril/Valsartan: Risk of Psychiatric Events
- Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Risk of Abnormal Uterine Bleeding
- Bortezomib: Risk of Guillain-Barré Syndrome and Demyelinating Polyneuropathy
- Mirtazapine: Risks of (i) Amnesia and (ii) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Ceftriaxone: Risk of encephalopathy
- Tumour Necrosis Factor alpha (TNFα): Kaposi’s Sarcoma
- Alemtuzumab (Lemtrada®): Revised indication, additional contraindications and risk minimisation measures
- Ondansetron: Information updates on risk of birth defects
- Abiraterone: Risk of hypoglycaemia due to drug interaction
- Clozapine: Risk of serious bowel complications caused by constipation
- Oseltamivir: Thrombocytopenia
- Mesalazine and sulfasalazine: Nephrolithiasis
- Efavirenz (including combination products): Risk of late onset neurotoxicity
- Safety Updates on COVID-19 Vaccine (Comirnaty®)
- Safety Alerts 2022
- Pneumococcal Polysaccharide Vaccine (23-Valent): Extensive Swelling of Vaccinated Limb
- Sorafenib: Risk of Thrombotic Microangiopathy (TMA)
- Hydroxychloroquine and Chloroquine: Risk of Hepatic Impairment
- Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]
- Methadone: Risk of Hypoglycaemia
- Piperacillin: Risk of Haemophagocytic Lymphohistiocytosis (HLH)
- Iodinated Contrast Media: Risk of Hypothyroidism (Particularly in Newborns and Young Children)
- Safety Updates on COVID-19 Vaccines: Risk of Tinnitus
- Labetalol: Risk of Nipple Pain and Raynaud's Phenomenon of the Nipple
- Sertraline: Risk of Microscopic Colitis
- Nirmatrelvir/ Ritonavir (PAXLOVID): Risk of Anaphylaxis and Hypersensitivity Reactions
- Brolucizumab (Pagenax®): Risk of Intraocular Inflammation, Including Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks)
- Alectinib (Alecensa®): Risk of Haemolytic Anaemia (New Warning and Precaution and Dose Modification Guidance)
- Metformin: Risk of Vitamin B12 Deficiency
- Corticosteroids (Systemic): Risk of Pheochromocytoma Crisis
- Loperamide: Risk of Acute Pancreatitis
- Chloroquine and Hydroxychloroquine: Risk of Psychiatric Disorders
- Empagliflozin: Risk of Tubulointerstitial Nephritis
- Olmesartan: Risk of Autoimmune Hepatitis
- Mavenclad® (Cladribine): Risk of Serious Liver Injury and New Recommendations About Liver Function Monitoring
- Azathioprine: Risk of Erythema Nodosum
- Safety Updates on COVID-19 Vaccines: Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) / Thrombosis with Thrombocytopenia Syndrome (TTS)
- Betamethasone (Systemic): Risk of Pheochromocytoma Crisis
- Hydrochlorothiazide, Chlorthalidone, Indapamide and Acetazolamide: Risk of Choroidal Effusion, Acute Myopia & Acute Angle-Closure Glaucoma
- Warfarin: Risk of Anticoagulant-Related Nephropathy (ARN)
- Tenofovir Alafenamide: Risk of Renal Adverse Effects
- Safety Alerts 2023
- [Updated] Loperamide: Risk of Acute Pancreatitis
- Ibrutinib (IMBRUVICA®): Package Insert Updates to Dose Modifications for Adverse Reactions and to Special Warnings and Precautions for Use
- Clomiphene: Risk of Serious Visual Disturbances Potentially Leading to Blindness
- Isotretinoin: Risk of Psychiatric Disorders and Sexual Dysfunction
- Cephalosporins: Risk of Seizures
- Valaciclovir: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- [Updated] Clindamycin (Systemic): Risk of Acute Kidney Injury
- Third-Generation Aromatase Inhibitors (Anastrozole; Exemestane; Letrozole): Risk of Tendon Disorders
- Statins: Risk of Inducing or Aggravating Myasthenia Gravis
- Terlipressin (Glypressin®): Serious or Fatal Respiratory Failure and Sepsis/Septic Shock in Patients with Type 1 Hepatorenal Syndrome (Type 1 HRS)
- Griseofulvin: Risk of Severe Cutaneous Adverse Reactions (SCARs)
- Comirnaty Vaccine: Risk of Heavy Menstrual Bleeding
- Azacitidine: Risk of Differentiation Syndrome
- Off-Label Use of Diclofenac Suppositories to Treat Fever in Children: Potential Risk of Acute Necrotising Encephalopathy of Childhood (ANEC)
- [Updated] Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate during Pregnancy
- [Updated] Pholcodine: Risk of Anaphylaxis to Neuromuscular Blocking Agents (NMBAs)
- Donepezil: Risk of QT Prolongation and Torsade de Pointes
- Safety Alerts 2024
- Hydroxychloroquine: Risk of Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)
- 17-Hydroxyprogesterone Caproate (17-OHPC): Potential Cancer Risk in Offspring Exposed in Utero and Limited Efficacy Data
- Azacitidine (Injectable Formulation): Risk of Cutaneous Vasculitis
- Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma
- Safety Signal Alert: Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)
- Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients
- Fluconazole: Updates on the Known Risk of Spontaneous Abortion During Pregnancy and Congenital Malformations in Children Exposed to Fluconazole in Utero
- Pseudoephedrine: Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)
- [Updated] 17-Hydroxyprogesterone Caproate (17-OHPC): Cancellation of Product Registration and Product Recall
- Anti-Clusters of Differentiation 20 (CD20) Antibodies (Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab): Risk of Pyoderma Gangrenosum
- Amoxicillin: Risk of Aseptic Meningitis
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration
- [Updated] Olmesartan: Risk of Autoimmune Hepatitis
- Proton Pump Inhibitors: Risk of Erectile Dysfunction
- Levetiracetam and Clobazam: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Hydrochlorothiazide: Risk of Acute Respiratory Distress Syndrome (ARDS)
- [Updated] Metformin: Risk of Vitamin B12 Deficiency
- Domperidone: Risk of Psychiatric Withdrawal Events When Used Off-Label for Lactation Stimulation
- Ciprofloxacin, Moxifloxacin, Levofloxacin and Ofloxacin (Fluoroquinolones) for Systemic Use (Oral and Injection): Risk of Suicidal Behaviours
- Imatinib: Risk of Thrombotic Microangiopathy
- Statins (Atorvastatin, Rosuvastatin, Simvastatin): Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis
- Rivastigmine: Risks of QT Prolongation and Torsade de Pointes
- Uncategorised
- Senarai Pengilang Kosmetik di Sistem QUEST
- Panduan Menjalankan Penyelidikan di Program Perkhidmatan Farmasi
- Persidangan Penyelidikan dan Pembangunan (R&D) Farmasi Kebangsaan Ke -12
- Kolaborasi R&D
- Garis Panduan & Borang
- Pelaporan Kesan Sampingan oleh Ubat-ubatan atau vaccine keatas Pengguna
- Laporan Tahunan Pusat Pemonitoran Kesan Advers Ubat
- Senarai Pengimport Berlesen di Sistem QUEST
- Senarai Pemborong Berlesen di Sistem QUEST
- Senarai Pengilang Berlesen di Sistem QUEST
- Produk Ubat Baru (NCE)
- Berita Keselamatan Ubat REAKSI
- Main Menu For Information (MAKLUMAT)
- New Drug Products (NCE)
- REAKSI Drug Safety News (Berita Keselamatan Ubat REAKSI)
- Laporan Tahunan Pusat Pemonitoran Kesan Advers Ubat
- Newsletter: Berita Ubat-ubatan (Buletin: Berita Ubat-ubatan)
- About NPCB
- Ahli MADRAC
- Piagam Pelanggan NPRA
- Anggota PBKD
- Ahli MADRAC
- Pengenalan MADRAC
- Berita PBKD
- Mengenai Pihak Berkuasa Kawalan Dadah (PBKD)
- Carta Organisasi
- OECD-GLP-MAD
- PIC/S
- Pusat Kolaborasi WHO Bagi Kawalan Regulatori Farmaseutikal
- Pengiktirafan dan Anugerah yang diterima NPRA
- Fungsi dan Peranan
- Tahap Pencapaian Perkhidmatan Tahun Terkini
- Healthcare Professional
- QUEST basic
- PENGUMUMAN
- Direktif Berkenaan Keperluan Mendaftar Penyelidikan Klinikal Sukarelawan Sihat Dengan National Healthy Research Volunteer Register (NHRVR) Kepada Sponsor/Pemohon/Penyelidik Yang Memohon Lesen Import Percubaan Klinikal (CTIL) Dan Kelulusan Mengilang (CTX) (3)
- Additional Indications Approved (2)
- Laporan Tahunan NPRA 2018
- Produk Baru Yang Diluluskan
- Tambahan Indikasi yang Diluluskan
- Pengumuman 2019
- SESI e-ENGAGEMENT: PELAKSANAAN PELAN BERFASA PEMERIKSAAN AMALAN PENGEDARAN BAIK (AEB) SECARA RUTIN KE ATAS PENGIMPORT DAN PEMBORONG PRODUK RANGKAIAN SEJUK / ‘TIME & TEMPERATURE SENSITIVE PRODUCT’ (TTSP)
- Pengilang Farmaseutikal, Radiofarmaseutikal dan Veterinar:Pembayaran Fi Pemeriksaan APB Secara Pra Bayar
- Pengilang Tradisional, Suplemen Kesihatan dan Kosmetik:Tindakan Regulatori kerana Kegagalan Menjelaskan Fi Pemeriksaan APB
- Peringatan: Pelaksanaan Kawalan Regulatori Bahan Aktif Farmaseutikal (API) Untuk Produk Yang Tamat Tempoh Pendaftaran Mulai 1 Januari 2020
- Peringatan: Pelaksanaan Kawalan Regulatori Bahan Aktif Farmaseutikal (API) Untuk Produk Yang Tamat Tempoh Pendaftaran Mulai 1 Januari 2020
- Permohonan Pembaharuan Lesen Pengilang / Mengimport / Pemborong untuk Tahun 2020
- Verifikasi Terjemahan Dokumen Rasmi
- Pengumuman 2021
- Penolakan Kajian Bioekuivalens (BE) yang Dijalankan oleh Pusat Kajian BE Synchron Research Services dan Panexcell Clinical Lab Susulan Penemuan Pemeriksaan United States Food and Drug Administration (US FDA)
- Direktif Berkenaan Keperluan Mendaftar Penyelidikan Klinikal Sukarelawan Sihat Dengan National Healthy Research Volunteer Register (NHRVR) Kepada Sponsor/Pemohon/Penyelidik Yang Memohon Lesen Import Percubaan Klinikal (CTIL) Dan Kelulusan Mengilang (CTX) (2)
- Pengumuman 2022
- Pengumuman 2023
- Pemakluman Pertukaran Tempat Penganjuran National Regulatory Conference (NRC) 2023 ke M Resort & Hotel, Kuala Lumpur
- Pengisytiharan Status Pendaftaran Produk di Negara Lain untuk Ubat Generik dalam Sistem QUEST
- Kajian Kepuasan Pelanggan NPRA
- Pemakluman Penggunaan Screening Checklist untuk Produk Generik (Prescription-Full)
- Bioequivalence
- Siaran Akhbar 2019
- Penjualan Produk Herba Untuk Memulih & Mencegah Demam Denggi
- Kenyataan Akhbar Kementerian Kesihatan Malaysia : Produk Tradisional Nan Bao (Capsule) Dikesan Mengandungi Racun Berjadual Sildenafil
- Kenyataan Akhbar KPK 1 April 2019 – Produk-Produk Kosmetik Yang Dikesan Mengandungi Racun Berjadual
- Kenyataan Akhbar KPK 29 Januari 2019 – Produk-Produk Kosmetik yang Dikesan Mengandungi Racun Berjadual
- Kenyataan Akhbar KPK 23 Mei 2019 -Produk-Produk Kosmetik Yang Dikesan Mengandungi Racun Berjadual
- Kenyataan Akhbar KPK 6 Ogos 2019 -Produk-Produk Kosmetik Yang Dikesan Mengandungi Racun Berjadual
- MedSafetyWeek2022
- 😊 Hey, are you a pharmacist? 💊
- 💊 How Medication Safety Works? 👨⚕️🏥👩⚕️
- 😊 Thank you for joining #MedSafetyWeek 💊
- 🤒 Have you ever experienced a side effect from a medicine? 😵
- 💫 When you report a suspected side effect from a medicine, we learn more about it 💡
- #MedSafetyWeek Starts Today! 💊
- Why do We Monitor the Safety of Medicines?🔎
- 🙋♂️ How Can You Help Us in Making Medicines Safer for Everyone? 🙋
- Get Ready for #MedSafetyWeek!
- MedSafetyWeek2021
- MedSafetyWeek2023
- Thanks for Joining #MedSafetyWeek 2023 💖
- Hello 👋 Are You a Pharmacist? 🧑⚕👩
- Hi! Are You a Nurse? 🏥
- Hey, Are You a Doctor? 👨⚕️🏥👩⚕️
- Sleep Troubles After Medication 😵? Remember to Report Them 📝
- Concerned About Side Effects? Remember to check 👀 , talk 🗣 , and tell 💬 this #MedSafetyWeek!
- 💊 Medications in Malaysia are Continually Monitored to Ensure Their Safety 🔎
- Preparations for #MedSafetyWeek are well underway – are you ready?
- 📣 #MedSafetyWeek kicks off today!
- Unexpected Side Effects Can Happen Anywhere, at Any Time: Your Report, Patients' Safety 💊
- Get Ready for #MedSafetyWeek 2023!
- MedSafetyWeek2024
- ❓ 5️⃣Questions to Ask Your Patients to Help Prevent Side Effects 💊
- 💊 Medicines Are Continually Monitored to Ensure Their Safety 🔍
- 🙏Thanks for Joining #MedSafetyWeek! 💊🌍
- 💊 Not All Medicines Are Equal ⚖️
- ❓ 5️⃣Questions to Ask Your Healthcare Professional to Help Prevent Side Effects 💊
- 📆 Join Us Next Week for #MedSafetyWeek!
- We’re Ready for #MedSafetyWeek – Are You? ⏱️
- 📣 #MedSafetyWeek Starts Today!
- 💊 Prevent Side Effects by Taking Medicines the Right Way! ✅
- Not All Medicines Are Suitable for Everyone 👶👧🏾👦👨🏻👴👵🤰🏻
- Dasar Privasi Aplikasi Mudah Alih
National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
- Phone: +603-7883 5400
More Links
More Links
DISCLAIMER
The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.
Site Last Modified
- Last Modified: Khamis 21 November 2024, 14:55:22.